STOCKSCREENR

REPL

NASDAQ

Replimune Group, Inc.

$2.50-0.07(-2.72%)Mkt Cap: $206.43M

Key Stats

Market Cap

$206.43M

P/E Ratio

-0.73

EPS

$-3.44

Dividend Yield

0.00%

52-Week Range

$1.50 — $13.24

Volume

3.44M

Avg Volume

4.62M

Beta

0.74

Price Alerts for REPL

Get alerted when REPL hits your target price.

$

Free — enter your email to get started

Valuation

P/E (TTM)

-0.73

Forward P/E

—

PEG Ratio

-4.11

P/S (TTM)

0.00

P/B (TTM)

3.42

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-1.03%

ROA (TTM)

-0.94%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.37

Current Ratio

5.60

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-0.12%

EPS Growth (5Y)

-0.16%

Sales Growth (3Y)

+0.00%

Sales Growth (5Y)

+0.00%

EPS Est (This Year)

$-3.12

EPS Est (Next Year)

$-2.12

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$2.92

Analyst Consensus

Price Target Range

$11.00$13.00$18.00
LowMedianHigh

Consensus Target: $13.75(450.0% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

82.57M

Float

76.57M

Free Float %

92.73%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2018-07-20

Employees

479

CEO

Sushil Patel

Index Membership

—

Website

https://www.replimune.com

Replimune Group, Inc. (REPL) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $206.43M, a P/E ratio of -0.73, REPL is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare REPL against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CYBN

Cybin Inc.

$8.28

+1.22%

$413.02M

ARMP

Armata Pharmaceuticals, Inc.

$8.89

-10.92%

$325.67M

CBIO

Crescent Biopharma, Inc.

$18.07

-19.22%

$498.22M

ZBIO

Zenas BioPharma, Inc.

$19.36

+0.21%

$864.29M

BHVN

Biohaven Ltd.

$9.63

+0.42%

$1.02B

ABUS

Arbutus Biopharma Corporation

$4.32

+2.86%

$850.78M

Frequently Asked Questions

What is Replimune Group, Inc.'s P/E ratio?

Replimune Group, Inc. (REPL) has a trailing twelve-month (TTM) P/E ratio of -0.73. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Replimune Group, Inc. pay a dividend?

No, Replimune Group, Inc. (REPL) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Replimune Group, Inc.'s market cap?

Replimune Group, Inc. (REPL) has a market capitalization of $206.43 million, classifying it as a micro-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.